Somatic rearrangements of the ret receptor tyrosine kinase have been consistently reported in papillary thyroid carcinomas (PTC). It is unclear whether the expression of wild-type c-ret may also be implicated in thyroid tumorigenesis. We studied ret mRNA expression in PTC from Norwegian patients. Using RT ± PCR, wild-type ret mRNA was detected in all of 22 PTC and in a PTC cell line. c-ret mRNA was clearly overexpressed in PTC as compared to non-neoplastic thyroid tissue. Hybridization using ret exon DNA dot blot arrays and complex cDNA probes con®rmed expression of ret RNA in thyroid biopsies. In accordance with the RNA data, Western immunoblotting showed evidence of wildtype Ret protein in PTC. Rearrangements generating the ret/PTC oncogenes co-existed with c-ret mRNA in PTC. Multiple alternative ret splicing variants were detected in PTC. Four novel ret splicing events were found in the region encoding the extracellular domain. The open reading frames of these transcripts were all in-frame with the Ret tyrosine kinase domain. In the central ret mRNA region encoding the cystein-rich, transmembrane, and main tyrosine kinase domains, no evidence of alternative splicing was detected. Two alternative splice events were detected in the ret mRNA encoding the C-terminal part of Ret protein harboring tyrosine residues important for Ret signaling, excluding exon 19, or retaining intron 19, respectively. Ribonuclease protection assays con®rmed the presence of ret alternative splicing events in thyroid biopsies. We conclude that in addition to ret/PTC rearrangements, wild-type c-ret mRNA and alternatively spliced ret transcripts are present in PTC. Transcriptional up-regulation and post-transcriptional mechanisms of c-ret RNA processing may contribute to dierences in expression of Ret protein observed in PTC compared to non-neoplastic thyroid tissue. Oncogene (2001) 20, 885 ± 892.
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The ret proto-oncogene encodes a transmembrane receptor tyrosine kinase as part of the receptor complex for the glial cell line derived neurotrophic factor (GDNF) ligand family (Airaksinen et al., 1999) . In papillary thyroid carcinomas (PTC), the most commonly detected genetic alterations of ret are translocations or inversions causing fusion of the ret tyrosine kinase domain to the 5'-part of other genes, generating the chimeric oncogenes ret/PTC (Santoro et al., 1999) . The regulatory region of the fusion partner gene controls ret/PTC expression, which is generally accepted to result in constitutive expression and activation of the Ret tyrosine kinase and subsequent downstream signaling. ret oncogene activation by rearrangements has been observed almost exclusively in PTC (Santoro et al., 1993) . In Hashimoto's thyroiditis, however, ret/PTC activation was found at a very high frequency without histologic evidence of PTC (Wirtschafter et al., 1997) .
The ret promoter has been regarded as silent in thyroid follicular cells and in tumors derived from these. Therefore, detection of either ret tyrosine kinase mRNA (Williams et al., 1996) or cytoplasmic Ret protein (Ishizaka et al., 1992; Viglietto et al., 1995 Tallini et al., 1998 has been interpreted as indicative of ret/PTC rearrangements in PTC . However, one study suggested discordance between the detection of ret/ PTC expression and ret tyrosine kinase mRNA, as ret/ PTC1 was detected in 8%, and ret tyrosine kinase mRNA in 70% of papillary carcinomas (Learoyd et al., 1998) .
Alternative ret mRNA 5'-splicing variants have been detected in tumor tissues (pheochromocytoma, medullary thyroid carcinoma), in non-neoplastic tissues including the thyroid (Lorenzo et al., 1995) , in cell lines (Xing et al., 1994) , and in the developing kidney (Ivanchuk et al., 1997) . ret 3'-splicing variants were also identi®ed (Myers et al., 1995; Ivanchuk et al., 1998) . The various ret splicing variants reported may aect the ligand-interacting or signaling properties of the receptor (Lorenzo et al., 1997; van Weering and Bos, 1998) .
In the course of studying gene expression in thyroid carcinomas, we detected wild-type ret transcripts in several thyroid biopsies. This ®nding was surprising, given the current knowledge of c-ret expression in the thyroid gland. We therefore investigated whether c-ret mRNA and protein actually were expressed in the thyroid, and especially in PTC known to harbor ret/ PTC rearrangements. Using RT ± PCR, ribonuclease protection assays, and DNA dot blot hybridization with complex cDNA probes, we found that incompletely and several novel alternatively spliced c-ret transcripts are frequently present in various types of thyroid tissue, including PTC biopsies and a PTC cell line. We report that c-ret mRNA and Ret protein are expressed in papillary carcinomas in addition to the chimeric ret/PTC transcripts.
Wild-type c-ret mRNA and protein in PTC
To test for the presence of c-ret speci®c RNA, we initially performed RT ± PCR (35 cycles) using primer pairs for the intracellular tyrosine kinase domain (Retex15-F/Retex19-R), and for the region encoding the transmembrane domain located to exon 11 (Retex9-F/Retex12-R) ( Table 1) . These experiments showed the presence of both ret tyrosine kinase (data not shown) and ret transmembrane/extracellular domain mRNA in each of the 36 biopsies investigated, including 22 PTC, four medullary carcinomas, two follicular adenomas, and also in samples of nonneoplastic thyroid tissue (representative samples in Figure 1a ). To estimate the dierences in amount of wild-type ret mRNA present in thyroid biopsies of various histologic type, a duplex RT ± PCR was performed using b-actin and c-ret speci®c primer sets (Table 1) . b-actin was co-ampli®ed as an internal control of RNA quality and amount, and the ®rst cycles detecting the b-actin and ret bands, respectively, were compared. The results of representative experiments are demonstrated in Figure 1b . In nonneoplastic thyroid biopsies, c-ret mRNA was not reliably detected until after 34 PCR cycles, thus indicating very low levels of mature c-ret mRNA. In contrast, c-ret was signi®cantly over-expressed in PTC samples. The level of wild-type ret mRNA in dierent PTC biopsies, normalized relative to the b-actin mRNA levels, was estimated to be in the range 1 ± 12%, as compared to the c-ret mRNA level in the medullary carcinoma biopsy (Figure 1b) .
Identi®cation of signi®cant amounts of wild-type ret mRNA indicated that the wild-type Ret protein could be expressed in PTC. We therefore performed protein immunoblot experiments using the three polyclonal antibodies sc-167g, sc-167, and anti-Ret TK . All three antibodies readily detected two bands of molecular weight approximately 155 and 175 kDa in protein extracts of medullary carcinoma biopsies (Figure 1c) , corresponding to the dierent glycosylated forms of wild-type Ret protein. These two protein bands could also be weakly, but distinctly, detected in some of the papillary carcinoma biopsies when loading the gel with a high amount of protein (200 ± 300 mg). In protein extracts of non-neoplastic thyroid biopsies Ret-speci®c bands were not observed (not shown). Protein bands corresponding to the chimeric ret/PTCs, or to the alternatively spliced c-ret transcripts, could not be reliably detected in the Western immunoblot experiments. Altered protein stability and rapid turnover of these putative Ret protein isoforms may reduce their amounts below the detection limit. However, such Ret protein variants might nevertheless have biological functions of importance.
Thus, we demonstrate the expression of signi®cant amounts of wild-type c-ret mRNA and Ret protein in PTC. RT ± PCR results could be in¯uenced by c-ret mRNA contamination from stromal cells, lymphocytes (Visser et al., 1996) , or parafollicular C-cells in normal thyroid tissue. These sources of ret transcripts are, however, unlikely as an explanation for the observed cret mRNA in papillary carcinomas since in situ hybridization did not show evidence of ret mRNA expression in lymphocytes or stromal cells (Lam et al., The notation of two temperatures (e.g. 61 ± 57) indicates the interval of annealing temperatures used when the actual primer was used in PCR Alternative splicing of c-ret in papillary carcinomas é Fluge et al Figure 1 c-ret mRNA and Ret protein expression in papillary carcinomas. The biopsies were processed as previously reported (Fluge et al., 2000) . Total RNA was extracted, DNase I treated (MessageClean Kit, Genhunter, Nashville, TN, USA), and subjected to ®rst-strand cDNA synthesis primed by oligo-dT 16 and random nucleotide hexamer, using Superscript II reverse transcriptase, and RNase H treated (Gibco ± BRL, Gaithersberg, MD, USA). One ml of the ®rst-strand reaction mixture was used as template in a 50 ml PCR. The primers and annealing temperatures used for PCR are given in Table 1 . Either Amplitaq (Perkin Elmer, Norwalk, CT, USA) or Advantage2 (Clontech, Palo Alto, CA, USA) was used in all PCR experiments (GeneAmp 2400, Perkin Elmer). Representative samples of each RT ± PCR product were sequenced in both directions with the appropriate primers (Table 1) , either directly after puri®cation (Qiaquick PCR Puri®cation Kit, Qiagen, Santa Clara, CA, USA), or after TA-cloning (pCR2.1-TOPO) (Invitrogen, San Diego, CA, USA) (Fluge et al., 2000) . (a) Representative samples from RT ± PCR using primers designed to detect a 565 bp wild-type c-ret fragment (primers Retex9-F/Retex 12-R, 35 PCR cycles). (b) For the semiquantitative assessment of c-ret mRNA, a duplex RT ± PCR was performed using the primers Retex9-F/Retex19-R amplifying a 1397 bp wild-type c-ret cDNA fragment, and a primer pair amplifying a 540 bp b-actin fragment included as an internal control of mRNA amount and quality. The PCR was performed in 100 ml initial reaction volume including 1 ml cDNA, Advantage2 (Clontech) was used as the polymerase, annealing temperature was 568C, and 10 ml aliquots were removed every third PCR cycle, from cycle 13 until cycle 34, and analysed on ethidium bromide stained agarose gels. Representative samples including a medullary carcinoma, two PTC, and one nonneoplastic thyroid specimen, are shown. The arrows indicate the 1397 bp ret and the 540 bp b-actin fragments. No c-ret speci®c RT ± PCR fragments were detected using cDNA made from ®broblast total RNA (not shown). (c) Parts of the histologically representative snap-frozen biopsies were crushed and proteins solubilized in extraction buer as reported (Fluge et al., 2000) . Approximately 250 mg protein from each biopsy was acetone precipitated, washed twice in acetone, dissolved in sample buer with b-mercaptoethanol, boiled for 10 min and separated on 7.5% SDS (sodium dodecyl sulphate) polyacrylamide gels. Electroblotting and blocking were performed as described. The membranes were then incubated for 2 h at room temperature with primary antibody diluted 1 : 400 in 1% dry milk. Ret protein was assessed by the goat polyclonal antibody sc-167 g (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (c, left panel), the rabbit polyclonal antibody sc-167 (Santa Cruz) (c, mid panel), and by the rabbit polyclonal anti-Ret TK antibody (Santoro et al., 1994 ) (c, right panel). After several washes in TBS-Tween, the membranes were incubated 1 h at room temperature with the secondary antibody, then washed with TBS-Tween and subjected to enhanced chemiluminescence (ECL) (Amersham). As secondary antibodies, sc-2020 (HRP-conjugated anti goat IgG) (Santa Cruz) diluted 1 : 6000 in 5% dry milk (c, left panel), or HRPconjugated donkey anti rabbit IgG) (Amersham, Chicago, IL, USA) diluted 1 : 500 in 1% dry milk (c, mid and right panels), were used. Negative controls omitting the primary antibody were run in parallel. The star (*) marks Ret protein expression also in papillary carcinomas. Abbreviations are; ptc: papillary thyroid carcinoma; mc: medullary carcinoma; fa: follicular adenoma; nt: nonneoplastic thyroid tissue; +RT: including reverse transcriptase in cDNA synthesis; 7RT: omitting reverse transcriptase from cDNA synthesis; M: molecular weight marker. The number given for each biopsy refers to the patient code number in our tissue bank 1998). The c-ret expression demonstrated in the human PTC cell line NPA further supports our interpretation that c-ret mRNA is expressed in PTC. Also, the very low levels of c-ret mRNA in the non-neoplastic biopsies (Figure 1b) argues against another source of expression than the tumor cells.
ret mRNA splice variants in PTC We further wanted to analyse for the presence of ret splicing variants using RT ± PCR with primer combinations covering the dierent regions of ret mRNA. In total, six ret splicing events aecting the coding region were identi®ed, ®ve of these have not been described previously ( Table 2 ). The relevant primer sequences are given in Table 1 . A schematic indication of the splicing events and positions of primers, related to c-ret mRNA, is presented in Figure 2f . In all RT ± PCR experiments, controls omitting the reverse transcriptase from the cDNA synthesis reactions were negative.
The region of c-ret mRNA encoding the extracellular and transmembrane domains was investigated using a forward primer in exon 1 (Retex1-F) and a reverse primer in exon 12 (Retex12-R). Five RT ± PCR fragments were generated, of which four were found to be ret-speci®c after cloning and DNA sequencing, three of these are shown in Figure 2a . The 2294 bp PCR-product corresponded to the wild-type ret mRNA (Takahashi et al., 1988 (Takahashi et al., , 1989 . A novel alternatively spliced c-ret transcript was detected, in which the segment corresponding to exons 4 ± 7 (897 nts) was lacking. The ret transcript harboring this splice event was designated ret3 ± 8 (Figure 2a ; Table 2 ). The ret3 ± 8 splicing was a frequent event in thyroid biopsies, being detected (35 PCR cycles) in all of seven PTC, four medullary carcinomas, one follicular carcinoma, in some samples of non-neoplastic thyroid tissue, and also in one pheochromocytoma analysed (Figure 2c ). The PTC cell line (NPA) also harbored the ret3 ± 8 splice variant (Figure 2b) . The ret3 ± 8 splicing was independently veri®ed by sequencing cDNA from biopsies from each of ®ve patients. Other novel transcripts, ret2 ± 8 (lacking exons 3 through 7), and ret1 ± 8 (lacking exons 2 through 7), were also identi®ed (Figure 2a ). An additional transcript (ret2 ± D3) in which exon 2 was joined to an alternative splice acceptor within exon 3 had a spliced-out segment encompassing 129 nucleotides, as compared to c-ret mRNA ( Table 2 ). The open reading frames of the ret1 ± 8, ret2 ± D3, ret2 ± 8, and ret3 ± 8 splicing variants were all predicted to be in-frame with the tyrosine kinase domain. Previously, three alternative splice variants located to the extracellular domain of c-ret have been identi®ed in a medullary carcinoma cell line (Lorenzo et al., 1995) . These variants, lacking either exon 3, exons 3 and 4, or exons 3, 4, and 5, were not detected in our thyroid biopsies. The splice variants in the extracellular domain reported previously and in the present study, may aect the interaction between Ret and the GDNFRa coreceptor/GDNF ligand complex (Treanor et al., 1996) . This diversity may provide opportunities for dierential ligand interaction and speci®c downstream signaling. No evidence of ret mRNA splicing was found in the region covering exons 8 ± 18, i.e. across the regions encoding the cystein-rich, transmembrane, and major tyrosine kinase domains. Multiple primer combinations (Table 1 ; Figure 2f ) covering this region were used, each experiment showing only one PCR product of expected wild-type size and sequence (not shown).
In the 3'-part of ret mRNA, two splicing events aecting the coding region were detected (Table 2, Figure 2f ). A ret transcript retaining intron 19 was identi®ed (Table 2) when the reverse primer Retint20-R, located in the alternative intron 20 (Myers et al., 1995) , was used in combination with a forward primer from exon 3 (Retex3-F). This splice variant has previously been described (Tahira et al., 1990) . The presence of intron 19 in ret mRNA aects the Cterminal region generating the Ret9 protein, as opposed to the Ret51 protein when exon 19 is spliced to exon 20 (Myers et al., 1995) . The Ret9 protein lacks Y1090 and Y1096, both targets for Grb2 interaction, but maintains the Shc interacting Y1062, providing The novel ret1 ± 8, ret2 ± D3, ret2 ± 8, ret3 ± 8 and ret18 ± 20 splicing variants have not been described previously. The spliced region denotes the number of nucleotides (nts) lacking as compared to the wild-type c-ret mRNA.
c The ret1 ± 8 denotes a splice event in which the 3'-end of exon 1 is joined to the 5'-end of exon 8 (lacking exons 2 through 7). The ret2 ± D3 denotes a splice event in which exon 2 is joined to an alternative splice acceptor within exon 3 (lacking 129 nucleotides of exon 3).
e Exons 18, 19 and 20 sequences according to Kwok et al. (1993) . Alternative splicing of c-ret in papillary carcinomas é Fluge et al Figure 2 Detection of alternatively spliced ret transcripts. cDNA was made from DNase I-treated total RNA from dierent thyroid tissue specimens, and subjected to PCR. The primer sequences and annealing temperatures used are indicated in Table 1 . The speci®city of each PCR-product was veri®ed by cloning and sequencing, as described. (a) RT ± PCR fragments generated from a PTC biopsy obtained using the primers Retex1-F/Retex12-R (Table 1 ). The ret splicing variants corresponding to each of these fragments are indicated (ret-wt, ret3 ± 8, ret2 ± 8, and ret1 ± 8). (b) Detection of alternatively spliced ret3 ± 8 transcripts in the PTC cell line NPA (de Nigris et al., 1998) . The NPA cell line was maintained in Dulbecco's modi®ed eagle medium (DMEM) with 10% fetal calf serum and 1% glutamine. (c) The presence of the ret3 ± 8 splice variant in several thyroid biopsy specimens is demonstrated by RT ± PCR (35 cycles) using the primers Retex3-F/Retex12-R amplifying a 977 bp fragment. (d) RT ± PCR products generated from a PTC biopsy using the primers Retex16-F/Retex21-R, showing the presence of c-ret mRNA including (ret-i20), or excluding (ret-wt), intron 20. (e) Demonstration of ret wild-type (ret-wt), and the ret18 ± 20 splicing event in two papillary carcinomas, using the primers Retex9-F/Retex21-R. (f) Alternatively spliced ret transcripts with the spliced regions marked relative to c-ret mRNA and ret exons. Ret exon 19 was designated 19a and 19b, and refers to the discrepancy in exon borders published by Ceccherini (19a) (Ceccherini et al., 1993) and Kwok (19b) (Kwok et al., 1993) . Arrows indicate the primers used in RT ± PCR. Abbreviations as in Figure 1 , and; fc: follicular carcinoma; pheo: pheochromocytoma Figure 3 ret splicing variants detected by ribonuclease protection assay (a and b) and ret RNA expression detected by hybridization using complex cDNA probes (c). Ribonuclease protection assays were performed using the RPA III kit (Ambion, Austin, TX, USA). The category of tissue used for extraction of total RNA is indicated below panel a and b. The protected fragments are indicated to the right of each panels a and b. The star marks the presence of the ret3 ± 8 (a), and the ret2 ± 8 spliced transcript (b). (a) To investigate the ret3 ± 8 splicing, a PCR was performed with primers Retex3-F and Retex9-R (Table 1) , using the DNA fragment harboring the 3 ± 8 splicing as template. The PCR-product was TA-cloned (pCR2.1-TOPO) (Invitrogen). Using a plasmid with the correct sequence and orientation as template, a new PCR product was generated using the primers M13F and Retex3-F, puri®ed and used as template in an 20 ml in vitro transcription reaction including 0.83 mM [a 32 P-UTP] and 5.0 mM`cold' UTP, 0.5 mM each ATP, CTP and GTP, and 20 units T7 RNA polymerase, at 378C for 15 min and then DNase I treated. The full-length probe was excised from a 5% polyacrylamide/ 8M urea gel, eluted, and its speci®c activity determined. This probe gives a 548 nts unprotected fragment, and a 478 nts protected fragment identifying the ret3 ± 8 transcript. Approximately 1610 5 c.p.m. of labeled probe was coprecipitated with 10 ± 30 mg total RNA from each thyroid biopsy. A mouse actin probe was also made and coprecipitated with 5 mg mouse liver total RNA. Yeast RNA (20 mg) with and without subsequent RNase treatment were also included. The hybridization, RNase digestion, and RNase inactivation were performed according to the descriptions. The protected fragments were separated on a 5% polyacrylamide/8M urea gel, transferred to ®lter paper, and exposed to phospho-imaging overnight. (b) DNA fragment harboring the ret2 ± 8 splicing event was used as template in a PCR with primers Retex1-F and Retex9-R (Table 1) . After TA-cloning and sequencing, the proper plasmid was digested with BamHI and used as template for in vitro transcription, as described. This probe gives a 722 nts unprotected fragment, and a 610 nts protected fragment identifying the ret2 ± 8 transcript. (c) Dot blot arrays of ret speci®c DNA fragments hybridized to radioactively labeled cDNA probes. Upper panel c: ret RNA expression in a papillary carcinoma. Lower panel c: ret RNA expression in a non-neoplastic thyroid tissue specimen from the contralateral lobe of the same patient. The DNA fragments were generated with PCR using intron primers and genomic DNA as the template. The primer sequences, annealing temperatures and Mg concentrations used to amplify ret exons 2 and 8 (Attie et al., 1995), ret exons 5, 9, 12, 14, and 18 (Mulligan et al., 1994) , ret exon 10 (Ceccherini et al., 1993) , and ret exon 16 (Landsvater et al., 1996) have been described. DNA fragments speci®c for ret exons 2, 5, 8, 9, 10, 12, 14, 16 and 18 , and a ret tyrosine kinase fragment (ret-TK), were then applied (approximately 50 ng DNA in each dot) on HybondN + membranes (Amersham, Chicago, IL, USA) prewetted in 106SSC. Denaturation, neutralization, UV-crosslinking, prehybridization, hybridization, washing, and phospho-imaging, were performed as described (Fluge et al., 2000) . The probes were generated by ®rst-strand cDNA synthesis from tumor or non-tumor total RNA, as described. The ®rst-strand cDNA was then phenol-chloroform extracted, ethanol precipitated, washed with 70% ethanol, air-dried, and dissolved in H 2 O to be used as template in a second-strand cDNA synthesis by the Klenow fragment of E. coli DNA polymerase I (Promega, Madison, WI, USA) (Feinberg and Vogelstein, 1983) with incorporation of [a 32 P]dCTP (370 mBq/ml) (Amersham), using random hexamer primers. Each probe mixture contained approximately 3610 7 c.p.m. in 30 ml total hybridization volume. Eight separate experiments were carried out comprising three PTC, one follicular adenoma, and four non-neoplastic thyroid tissue specimens (macro-and microscopically representative normal tissue from the contralateral lobe). A ®broblast complex cDNA probe was negative in this assay Alternative splicing of c-ret in papillary carcinomas é Fluge et al possible signal divergence at this point (van Weering and Bos, 1998) . Using a reverse primer in exon 21 (Retex21-R) and forward primers in either exon 9 (Retex9-F), or in exon 16 (Retex16-F), PCR fragments were generated which corresponded to the wild-type cret sequence including intron 20 (ret-i20), or excluding intron 20 (ret-wt) ( Figure 2d ; Table 2 ). Also one additional PCR-fragment (1931 bp) was shown to represent an alternatively spliced ret transcript in which exon 19 (Kwok et al., 1993) was lacking, the spliced-out region encompassing 60 nts as compared to wild-type ret mRNA, thus joining exon 18 directly to exon 20 ( Figure 2e ; Table 2 ). This ret18 ± 20 splicing event removed 20 amino acids including Y1060 from the C-terminal part, but retained the 51 amino acids in the tail (including Y1090 and Y1096) of Ret protein inframe. All splice donor sites were located at published exonintron borders (Table 2) , having the normal gt/ag intron consensus pattern. Most of the splicing events were detected in several independent biopsy samples. Furthermore, ribonuclease protection assays were performed to con®rm the authenticity of selected splicing events. The results of two experiments are shown in Figure 3a and b. From two medullary carcinomas and a PTC biopsy, a protected band was generated (478 nts) corresponding to the ret3 ± 8 splicing (Figure 3a) . The presence of separate protected bands corresponding to exon 3 (274 nts), and to exon 8a (204 nts), also con®rmed the presence of wild-type ret transcripts. Furthermore, a band was seen in the two medullary carcinomas, but not reliably in the PTC biopsies, which of size was in accordance with a 159 nts protected fragment corresponding to the ret2 ± D3 splicing event. Using a riboprobe harboring the ret2 ± 8 splicing, the expected protected fragment (610 nts) could be demonstrated in a medullary carcinoma biopsy (Figure 3b ). The protected fragments corresponding to wild-type ret mRNA (406 and 204 nts, Figure 3b ) were also seen.
To analyse for ret RNA expression in thyroid tissues, we also carried out dot blot array experiments using DNA fragments from c-ret exons 2, 5, 8, 9, 10, 12, 14, 16 , and 18 on the membranes. Hybridization reactions were performed using 32 P-labeled cDNA probes made from total RNA isolated from three papillary carcinomas, one follicular adenoma and four non-neoplastic thyroid tissue samples. Representative results are given in Figure 3c . c-ret RNA was expressed in each thyroid biopsy investigated. Hybridization to DNA fragments corresponding to ret mRNA segments encoding both the extracellular and the intracellular domains was seen. This dot blot hybridization assay does not distinguish between maturely spliced and unspliced nuclearly retained ret transcripts.
Our RNA expression data indicate that ret gene transcription is active in both PTC and non-neoplastic tissues. However, we speculate that the regulation of ret transcription, splicing, and nuclear export may operate signi®cantly more eciently in PTC than in non-neoplastic thyroid follicular cells, thereby generating a large dierence in the level of maturely spliced ret transcripts. A recent study (Wilson et al., 1999) supports a dierentially controlled mechanism for precursor mRNA splicing and export. This would also be consistent with the post-transcriptional silencing mechanism of c-ret observed in a medullary carcinoma cell line (TT) (Carson-Walter et al., 1998) .
Analysis of ret/PTC transcripts was performed on selected PTC biopsy samples and showed that wildtype c-ret mRNA could co-exist with ret/PTC. ret/ PTC1 was detected in four out of 14 PTC, ret/PTC2 in ®ve out of 12 PTC, and ret/PTC3 in four out of 14 PTC (not shown). While c-ret RNA could be readily detected from all of the PTC biopsy specimens by RT ± PCR, ret/PTC expression could only be detected after RT-PCR and subsequent Southern hybridization, indicating very low steady state expression levels of the chimeric transcripts (data not shown).
Taken together, we demonstrate that signi®cant amounts of c-ret mRNA are present in PTC. Extensive splicing in the mRNA regions encoding the extracellular domain and the C-terminal part of Ret protein provides diversity predicted to aect the ligandinteracting properties and downstream signaling of the receptor, respectively. The c-ret exons 8 ± 18, encoding the cystein-rich, transmembrane, and major tyrosine kinase domains, seem not to be subjected to alternative splicing. We conclude that transcriptional and post-transcriptional mechanisms of ret RNA processing may contribute to the dierential expression of Ret protein in papillary carcinomas compared to non-neoplastic thyroid tissue, and that wild-type and alternatively spliced ret transcripts co-exist with ret/ PTC rearrangements and may play a role in thyroid tumorigenesis.
Note added in proof After this work was submitted for publication, a study (Bunone et al., 2000) demonstrated the presence of wildtype ret transcripts in thyroid follicular cells and in PTC, also in tumor specimens harboring ret/PTC activation. Moreover, in a PTC cell line, they found that the Ret receptor was tyrosine phosphorylated by GDNF, indicating that Ret was active in these cells. Their data are consistent with our present report.
